Launch of a new 18F-PSMA-1007 production line

S.R.Y. has successfully developed and implemented a production line for an innovative material used to diagnose prostate cancer and its metastases. The material is based on PSMA (Prostate specific membrane antigen) and is labeled with 18F.

Today, the most common material in the world for imaging prostate cancer is 68Ga-PSMA, which led to a revolution in the field of imaging in the diagnosis of prostate cancer, with its entry into regular use in 2012.

The advantages of 68Ga-PSMA are:

Increased early diagnosis ability

Improved uptake in tumors

Low background and ability to diagnose metastases, including in small lymph nodes

However, 68Ga-PSMA has several disadvantages:

Relatively low resolution, resulting from the use of the 68Ga isotope

Significant renal clearance and accumulation in the bladder, which limits diagnostic ability

Short half-life, which limits its distribution to distant targets

Limited throughput (3-4 doses per production batch)

The use of generators forces the manufacturer to depend on a third party

As of 2017, the availability and price of generators has been a real challenge

During 2017, several studies were published in the international scientific literature that dealt with the development of an innovative marker based on PSMA and labeled with 18F, namely 18F-PSMA-1007

18F-PSMA-1007 is a marker with improved clinical and pharmacological properties compared to 68Ga-PSMA, which allows for better logistical operation and is attracting great attention among the international nuclear medicine community

The advantages of 18F-PSMA-1007 are:

Improved resolution, resulting from the use of the 18F isotope

Rapid clearance mediated by the liver (hepatobiliary clearance) and reduced absorption in the bladder

Degree of labeling High

Ideal half-life

High-throughput production capacity (high number of doses)

Independent production without dependence on a third party

Improved tumor uptake and high sensitivity, with an emphasis on disease recurrence at very low PSA levels

In light of the outstanding advantages of this material, S.R.Y. launched a regular production line for 18F-PSMA-1007 in 2017

Share:

Contact Us

S.R.Y. (Specialized Medical Services) is an Israeli company that manufactures and develops radiopharmaceuticals for diagnosis, treatment and medical research. The company operates the cyclotron unit at Hadassah Ein Kerem Hospital and produces medical isotopes in an advanced nuclear pharmacy.

Contact details

All information on this site is general only and should not be considered in any way medical advice, treatment recommendation, a substitute for treatment, or a recommendation for a pharmaceutical preparation. Therefore, the content and information should not be relied upon for the purpose of receiving or providing medical treatment, and the information is not a substitute for the instructions in the consumer leaflet or for consultation with a qualified medical professional.
S.R.Y. (Specialized Medical Services) strives to provide as up-to-date and reliable information as possible on this site, but does not guarantee the completeness or completeness of the information on the site. Any use of the information on the site is the sole responsibility of the users.

Accessibility Toolbar